SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR Gold Trust - SPDR Gold Shares ETF

SPDR Gold Shares ETF

GLD is trending as gold prices reach new all-time highs, fueled by economic uncertainty and speculation around central bank policies. The community is debating whether this rally is sustainable or indicative of a larger global financial shift, with some pointing to potential overbought conditions while others highlight ongoing global demand. Discussions also involve gold's role as a safe haven asset amidst concerns about the dollar and potential market corrections.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending amid a debate about its valuation, with some traders pointing to potential overvaluation and comparisons to past market bubbles. The community is actively discussing shorting opportunities and potential downside, while others remain bullish, citing the future potential of quantum computing. Recent price action and sector-wide trends in quantum computing stocks are also contributing to the heightened interest.

Bitfarms Ltd. (Canada) engages in the business of mining cryptocurrency. The firm is also involved in the ownership and operation of server farms comprised of computers designed for the purpose of validating transactions on the Bitcoin blockchain. The company was founded by Emiliano Joel Grodzki and Nicolas Bonta in 2017 and is headquartered in Toronto, Canada.

Bitfarms Ltd.

Bitfarms is trending due to a proposed offering of convertible senior notes, sparking mixed reactions within the community. While some express concern over potential dilution, others view it as a strategic move for long-term growth and expansion into AI and high-performance data centers, especially with comparisons to similar moves by sector peers. The community is actively debating the implications of the offering and its effect on the stock's future trajectory.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

Cipher Mining is trending as investors discuss its potential in the AI data center space, fueled by rumors of a deal with a major hyperscaler and recent completion of its Black Pearl Phase 1. Community members are weighing the impact of these developments against broader market volatility and profit-taking, while also considering recent analyst upgrades and potential for a short squeeze. The stock's connection to Bitcoin's performance and the overall AI sector's growth is also a key talking point.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending as investors discuss its potential in the AI cloud services sector, fueled by a recent analyst upgrade and a successful convertible notes offering. Community chatter revolves around IREN's move beyond Bitcoin mining and its increasing focus on AI infrastructure, with some drawing comparisons to other high-growth stocks. Discussions also include perspectives on market manipulation, short squeezes, and potential price targets.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood's price action is volatile, with community members debating whether recent dips are buying opportunities or signs of a larger correction. Some traders point to the stock's correlation with crypto markets and overall market sentiment as drivers. Anticipation for upcoming earnings is building, with some expecting a strong report while others express concerns about valuation and potential manipulation.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

ONDS is trending as the community discusses its recent volatility, particularly after a significant drop that some attribute to market-wide pressures or potential profit-taking following a substantial run-up. Community members are actively debating the company's valuation, potential catalysts, and the impact of recent partnerships. Some traders express confidence in a rebound, while others remain cautious, pointing to broader market concerns and the stock's high valuation relative to current revenue.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending due to volatility following a recent surge, with community discussions focused on potential shareholder dilution from executive stock sales and skepticism about management. Political factors, specifically comments about drug prices, are also impacting sentiment, while some traders see a short squeeze opportunity amidst ongoing debates about the company's long-term prospects after their new menopause offerings.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy is trending amidst discussions about its correlation with Bitcoin's price movements and potential S&P 500 inclusion; the community is weighing the company's future, with some expressing concerns about its performance and others anticipating a rebound as Bitcoin gains traction. Talk about Michael Saylor has come to the forefront as well.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

NVTS is trending as investors discuss its potential due to its partnership with NVDA, with many community members expressing bullish sentiment and anticipating further gains. Some traders are weighing short-term pullbacks against the long-term potential tied to AI data centers, while others point to a possible short squeeze. Community members are actively debating valuation, potential buyout scenarios, and the impact of broader market trends.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Roche Wins FDA Nod for Label Expansion of Tecentriq in Lung Cancer

Roche gains FDA approval for Tecentriqs expanded label, marking the first combo maintenance therapy for extensive-stage small cell lung cancer. 

Can Auvelity Drive Axsome's Growth Through the Rest of 2025?

AXSM's Auvelity drives 82% sales growth in the first half of 2025, with label expansion studies and other marketed products bolstering its CNS drug portfolio.

Here's Why JAZZ Stock Is an Unconventional Cannabis Investment

Jazz Pharma is redefining cannabis investing with Epidiolex, a fast-growing FDA-approved epilepsy drug fueling its growth.

Axsome Shares Up 20% in a Month: How Should You Play the Stock?

AXSM shares rise 20.2% in a month, powered by booming Auvelity sales and a growing CNS drug pipeline.

JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug

Jazz Pharmaceuticals strikes a $1B licensing deal with Saniona for SAN2355, an epilepsy drug designed to target seizure control more precisely.

Don't Overlook Jazz (JAZZ) International Revenue Trends While Assessing the Stock

Evaluate Jazz's (JAZZ) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

Jazz Pharmaceuticals experienced increased retail chatter on Wednesday after the U.S. Food and Drug Administration (FDA) granted accelerated approval to Modeyso (dordaviprone)&nbsp;for the treatment of a specific form of brain tumor.The drug is approved to treat adult and pediatric patients aged one year and older with diffuse midline glioma carrying an H3 K27M mutation, following progression after prior therapy. Continued approval may depend on confirmatory results from the Phase 3 ACTION trial.Modeyso is the first FDA-approved therapy for this rare and aggressive brain tumor, which affects an estimated 2,000 people in the U.S. annually, many of them children and young adults, according to the company.The oral, once-weekly capsule is expected to be commercially available in the coming weeks. The FDA based its decision on data from 50 patients enrolled across five open-label studies. About 1 in 5 patients responded to treatment, with responses lasting a median of just over 10 months.&nbsp;Among those who responded, nearly three-quarters saw benefits for at least six months, and more than a quarter maintained their response for at least a year.Patrick Wen of Dana-Farber Cancer Institute called the approval a “major turning point in neuro-oncology,” noting that Modeyso introduces a new treatment option for a population with limited choices.&nbsp;About a third of glioma patients in the trial experienced serious side effects on Modeyso, including hydrocephalus, seizures, vomiting, and muscle weakness. Fatigue, nausea, and headaches were the most common complaints.Separately, Truist Securities reduced its price target on Jazz Pharmaceuticals to $200 from $230, citing slower momentum in Epidiolex and cancer therapies such as Rylaze and Zepzelca.&nbsp;In the second quarter, Rylaze revenue dropped 7% to $100.7 million, and Zepzelca sales slipped 8% to $74.5 million. Epidiolex posted modest 2% growth to $251.7 million.&nbsp;Truist noted that the company’s total revenue was propped up by strong momentum in the oxybate franchise, where the lead drug, Xywav, rose 13% to $415.3 million. However, it flagged potential headwinds from two upcoming non-oxybate narcolepsy treatments nearing FDA review.On Stocktwits, retail sentiment for Jazz Pharmaceuticals was ‘extremely bullish’ amid ‘high’ message volume.<a href="https://stocktwits.com/symbol/JAZZ">Jazz Pharmaceuticals’ stock</a> has declined 14.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Jazz Pharmaceuticals (JAZZ) experienced increased retail chatter on Wednesday after the U.S. Food and Drug Administration (FDA) granted accelerated approval to Modeyso  (Photo credit: Getty Images)

Retail Traders Cheer Jazz Pharma After FDA Clears Rare Drug For Brain Tumor

The approval was based on pooled data from 50 patients in five open-label trials, showing an overall response rate of 22%, with a median response duration of 10.3 months.

Equity

JAZZ Stock Down on Wider-Than-Expected Q2 Loss, '25 Sales View Cut

Jazz shares slide as Q2 loss widens on Chimerix charge, with 2025 sales outlook trimmed despite higher EPS guidance.

Jazz (JAZZ) Reports Q2 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Jazz (JAZZ) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Jazz Pharmaceuticals (JAZZ) Reports Q2 Loss, Misses Revenue Estimates

Jazz (JAZZ) delivered earnings and revenue surprises of -34.80% and -0.26%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Jazz Pharmaceuticals plc

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

JAZZ
Jazz Pharmaceuticals plc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest JAZZ News

JAZZJazz Pharmaceuticals plc